Enteris BioPharma is the partner of choice for developing oral BCS-III and BCS-IV drug products, including oral peptides, peptidomimetics, and small molecules. The Peptelligence® and ProPerma® oral drug delivery technologies have been proven safe and effective in numerous clinical trials, enabling significant treatment opportunities for which there is no oral delivery option. With a purpose-built, state-of-the-art facility, Enteris offers end-to-end oral drug product development from formulation and proof-of-concept to clinical and commercial manufacturing for the most challenging APIs.
The Peptelligence® and ProPerma® technologies provide oral bioavailability enhancement of challenging BCS-III and BCS-IV compounds by uniquely improving both permeability and solubility.
Enteris supports our partners through all stages of solid oral dosage form development from formulation and analytical method development to cGMP clinical and commercial manufacturing.
Enteris works with our partners through the various stages of development, from a robust proof-of-concept feasibility program through commercial manufacture utilizing our extensive CMC capabilities.